3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Glioblastoma
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Renal Insufficiency
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lung Neoplasms
1
Liver Failure
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Nivolumab
3
Cisplatin
3
atezolizumab
2
Irinotecan
2
Ipilimumab
2
Etoposide
2
Carboplatin
2
tivozanib
1
repotrectinib
1
niraparib
1
gallium Ga 68 dotatate
1
dostarlimab
1
cabozantinib
1
budigalimab
1
belinostat
1
Topotecan
1
Temozolomide
1
Specimen Handling
1
Radiosurgery
1
Radionuclide Imaging
1
Positron-Emission Tomography
1
Positron Emission Tomography Computed Tomography
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Immunoglobulin G
1
IFL protocol
1
Fluorouracil
1
Disulfides
1
DLL3 protein, human
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
veliparib
×
90 days
×
Clear all
No trials found.